Skip to content

TuHURA Biosciences, Inc. HURA Operating Lease Liabilities

Operating Lease Liabilities at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$3.5M-40.8%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
$406K-51.3%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$33.15M+0.2%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$0-100%
Janux Therapeutics logo
Janux TherapeuticsJANX
$19.1M-8.2%

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s operating lease liabilities?
TuHURA Biosciences, Inc. (HURA) reported operating lease liabilities of $250.08K in Q1 2026.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.